Glenmark Pharmaceuticals Quarterly Results for Trading Insights
In Mar 2026, Glenmark Pharmaceuticals (GLENMARK) reported revenue ₹3,949 Cr and net profit ₹301 Cr — revenue +22.2% YoY. Also explore GLENMARK share price history to track price trends across different timeframes.
GLENMARK Quarterly Results — Revenue, Profit & EPS Highlights
Glenmark Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Glenmark Pharmaceuticals screener.
- Revenue of ₹3,949 Cr in Mar 2026 (-36.3% vs Sept 2025, +22.2% vs Mar 2025)
- Net Profit of ₹301 Cr in Mar 2026 (-50.7% vs Sept 2025, +7425.0% vs Mar 2025)
- EBITDA of ₹568 Cr in Mar 2026 (-49.8% vs Sept 2025)
- Operating Margin of 10.0% in Mar 2026 (-6.0pp vs Sept 2025)
- Earnings Per Share of ₹10.68 in Mar 2026 (-50.6% vs Sept 2025)
Glenmark Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GLENMARK quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 3,949 | 6,204 | 3,232 | 3,086 | 3,933 | -36.3% | 22.2% |
| Net Profit (₹ Cr) | 301 | 610 | 4 | 47 | 403 | - | - |
| EBITDA (₹ Cr) | 568 | 1,132 | 164 | 79 | 717 | - | - |
| EPS (₹) | 10.68 | 21.63 | 0.16 | 1.66 | 14.29 | - | - |
| Operating Margin (%) | 10.0% | 16.0% | 5.0% | 2.0% | 17.0% | - | - |
GLENMARK Share Price Trend — 1-Year Movement Across Quarterly Results
Glenmark Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse GLENMARK financial statements for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GLENMARK vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Glenmark Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹191,454.40 Cr | 4961.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.1 |
|
Zydus Life Science
Mar 2026 |
₹115,616.29 Cr | 1108.7 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
|
Cipla
Mar 2026 |
₹114,318.19 Cr | 1410.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.3 |
All amounts in ₹ Crores